To investigate the predictive factors of clinical outcome of selective retina therapy (SRT) for diabetic macular edema (DME).
This retrospective study included 22 eyes of 22 patients (15 males and 7 females), who were treated with SRT for DME at the Department of Ophthalmology of Osaka City University Hospital and observed at least 6 months after the treatment. The mean age was 64 years (range 40–81). Thirteen of the 22 eyes (59%) had a treatment history other than SRT before. SRT laser (527 nm, 1.7 µs, 100 Hz) was used for treatment. Changes in the best-corrected visual acuity (BCVA) (logMAR) and central macular thickness (CMT) in optical coherence tomography were examined at baseline, 3-month follow-up, and 6-month follow-up. Factors associated with the rate of change in CMT at 3 and 6 months after SRT were examined.
The mean BCVA (logMAR) was 0.26 ± 0.31, 0.22 ± 0.27 and 0.23 ± 0.29 at baseline, 3 months and 6 months, respectively (p = 0.15 at 3 months, 0.40 at 6 months; compared to baseline). The mean CMT was 502 ± 163, 493 ± 204, and 416 ± 185 μm at baseline, 3 months, and 6 months, respectively (p = 0.69 at 3 months, 0.01 at 6 months; compared to baseline). The multivariate analysis found a significant negative association with previous macular photocoagulation (p = 0.03) at 3 months and a positive association with a history of insulin use (p = 0.02) and previous panretinal photocoagulation (p = 0.03) at 6 months after SRT.
The CMT was significantly decreased at 6 months after SRT in DME. The history of insulin use and panretinal photocoagulation may positively and the history of macular photocoagulation may negatively affect the outcome of SRT, which must be considered when determining the therapeutic indications for SRT.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136
Tan GS, Cheung N, Simo R, Cheung GC, Wong TY (2017) Diabetic macular oedema. Lancet Diabetes Endocrinol 5:143–155
Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. ETDRS report number 1. Arch Ophthalmol 103:1796–1806
Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, Di Tizio FM, Frisone G, Marchi S (2005) Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 25:840–845
Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245–251
Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115–1128
Laidlaw DA (2008) Vitrectomy for diabetic macular oedema. Eye (Lond) 22:1337–1341
Diabetic Retinopathy Clinical Research Network Writing Committee (2010) Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087–1093
Simunovic MP, Hunyor AP, Ho IV (2014) Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol 49:188–195
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins J (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022
Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203
Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW (2015) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:375–381
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182
Park SJ, Choi Y, Na YM, Hong HK, Park JY, Park KH, Chung JY, Woo SJ (2016) Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Investig Ophthalmol Visual Sci 57:2612–2617
Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R (1999) Retinal sparing by selective retinal pigment epithelial photocoagulation. Arch Ophthalmol 117:1028–1034
Brinkmann R, Roider J, Birngruber R (2006) Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 302:51–69
Roider J, Liew SH, Klatt C, Elsner H, Poerksen E, Hillenkamp J, Brinkmann R, Birngruber R (2010) Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes’s Arch Clin Exp Ophthalmol 248:1263–1272
Park YG, Kim JR, Kang S, Seifert E, Theisen-Kunde D, Brinkmann R, Roh YJ (2016) Safety and efficacy of selective retina therapy (SRT) for the treatment of diabetic macular edema in Korean patients. Graefes’s Arch Clin Exp Ophthalmol 254:1703–1713
Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes’s Arch Clin Exp Ophthalmol 244:1638–1645
Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83–88
Yasui A, Yamamoto M, Hirayama K, Shiraki K, Theisen-Kunde D, Brinkmann R, Miura Y, Kohno T (2017) Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy. Graefes’s Arch Clin Exp Ophthalmol 255:243–254
Klein KA, Cleary TS, Reichel E (2017) Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Int J Retina Vitreous 3:16
Kang SW, Park CY, Ham DI (2004) The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol 137:313–322
Roider J, Hillenkamp F, Flotte T, Birngruber R (1993) Microphotocoagulation: selective effects of repetitive short laser pulses. Proc Natl Acad Sci U S A 90:8643–8647
Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R (2000) Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol 84:40–47
Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R (2008) Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med 40:616–624
AbdelKader DH, Osman MA, Elgizawy SA, Faheem AM, McCarron PA (2016) The Role of insulin in wound healing process: mechanism of action and pharmaceutical applications. J Anal Pharm Res 2:00007
Leschey KH, Hackett SF, Singer JH, Campochiaro PA (1990) Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 31:839–846
Stefánsson E, Machemer R, de Juan E Jr, McCuen BW II, Peterson J (1992) Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am J Ophthalmol 15:36–38
Tejada S, Batle JM, Ferrer MD, Busquets-Cortés C, Monserrat-Mesquida M, Nabavi SM, Del Mar Bibiloni M, Pons A, Sureda A (2019) Therapeutic effects of hyperbaric oxygen in the process of wound healing. Curr Pharm Des 25:1682–1693
Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, Abdelfattah N, Kuppermann B, Csaky KG, D’Argenio DZ, Burke JA, Hughes PM, Robinson MR (2010) Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci 51:2135–2138
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents a review of literature. Eye (Lond) 27:787–794
Tolentino M (2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 56:95–113
Nguyen-Khoa BA, Goehring EL, Werther W, Fung AE, Do DV, Apte RS, Jones JK (2012) Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol 12:11
Sim DA, Keane PA, Tufail A, Egan CA, Aiello LP, Silva PS (2015) Automated retinal image analysis for diabetic retinopathy in telemedicine. Curr Diabetes Rep 15:14
Simo R, Sundstrom JM, Antonetti DA (2014) Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37:893–899
Ohkoshi K, Yamaguchi T (2010) Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 149:133–139
Luttrull JK, Dorin G (2012) Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 8:274–284
Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A (2015) Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561–577-nm) direct photocoagulation for diabetic macular edema. Jpn J Ophthalmol 59:21–28
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the ethics committee of our hospital, carried out on the basis of the Declaration of Helsinki, and registered with the University Hospital Medical Information Network (UMIN) (No. 000010471).
Written informed consent was obtained from all patients prior to enrollment.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yamamoto, M., Miura, Y., Hirayama, K. et al. Predictive factors of outcome of selective retina therapy for diabetic macular edema. Int Ophthalmol 40, 1221–1232 (2020). https://doi.org/10.1007/s10792-020-01288-6
- Macular edema
- Diabetic retinopathy
- Laser therapy
- Retinal pigment epithelium